CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial
Taiwanese pharma company Center Laboratories (CenterLab) said that its anti-diabetic drug candidate CS02 has met the primary endpoint of a phase 2 clinical trial. According ... Read More
KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal anti-VEGF antibody biopolymer conjugate KSI-301 for the ... Read More
CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial
Taiwanese pharma company Center Laboratories (CenterLab) said that its anti-diabetic drug candidate CS02 has met the primary endpoint of a phase 2 clinical trial. According ... Read More
Moderna completes enrollment for phase 2 trial of mRNA-1273
Moderna said that it has concluded enrollment for the two cohorts of the phase 2 study of its COVID-19 vaccine candidate mRNA-1273. According to the ... Read More
Curis doses first patient in CA-4948 phase 1 clinical trial in AML and MDS
CA-4948 phase 1 clinical trial : US biotech company Curis said that it has dosed the first patient with CA-4948 in a phase 1 clinical ... Read More
Sinovac Biotech gets approval for CoronaVac phase 3 trial in Brazil
CoronaVac phase 3 trial : Sinovac Biotech, a Chinese biopharma company has secured approval in Brazil to begin a phase 3 clinical trial for CoronaVac, ... Read More
Unum Therapeutics acquires kinase inhibitors developer Kiq
Unum Therapeutics, a US biopharma company, has acquired Kiq, a biotech company focused on the discovery and development of precision kinase inhibitors, in an all-stock ... Read More
Gilead Sciences announces Veklury EU approval for COVID-19 treatment
Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 ... Read More
ViiV Healthcare bags Rukobia FDA approval for HIV patients with limited treatment options
Rukobia FDA approval : ViiV Healthcare said that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets as a ... Read More
Medivir gets orphan medicinal product designation for MIV-818 for HCC in EU
Swedish biotech company Medivir has secured orphan medicinal product designation from the European Commission for MIV-818 for the treatment of hepatocellular carcinoma (HCC). The orphan ... Read More